The notices it replaced
- Reissues: PA-20-265 PHS 2020-2 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 2 steps back: PA-19-270 PHS 2019-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed
- 3 steps back: PA-18-575 PHS 2018-02 Omnibus Solicitation of the NIH, CDC, and FDA for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42] Clinical Trial Not Allowed)
- 4 steps back: PA-17-303 PHS 2017-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 5 steps back: PA-16-303 PHS 2016-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 6 steps back: PA-15-270 PHS 2015-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 7 steps back: PA-14-072 PHS 2014-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42]
- 8 steps back: PA-13-235 Reissue PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 9 steps back: PA-13-089 PHS 2013-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 10 steps back: PA-12-089 PHS 2012-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 11 steps back: PA-11-097 PHS 2011-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 12 steps back: PA-10-051 PHS 2010-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
- 13 steps back: PA-09-081 PHS 2009-02 Omnibus Solicitation of the NIH for Small Business Technology Transfer Grant Applications (Parent STTR [R41/R42])
Replaced by PA-22-178.
Who won it before
1,738 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $585,375,964 in first-year total cost, median $256,579.
Most frequent study sections
- Special Emphasis Panel[ZRG1 SBIB-T (10)]101
- Special Emphasis Panel[ZRG1 OTC-T (10)]81
- Special Emphasis Panel[ZRG1 ETTN-G (12)]62
- Special Emphasis Panel[ZRG1 ETTN-M (11)]55
- Special Emphasis Panel[ZRG1 BCMB-G (10)]52
Most frequent institutions
- FOX CHASE CHEMICAL DIVERSITY CENTER, INC18
- L2 DIAGNOSTICS, LLC13
- MEDOSOME BIOTEC, LLC10
- ARREVUS, INC.8
- MICROBIOTIX, INC8
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Focal seizure monitoring with a consumer wearable: algorithmic development and validation1R41NS130958-01 | CRONE, NATHAN E | EPIWATCH, INC., MD | $275,547 | ZRG1 |
| 2023 | Chemical-based Nitric Oxide Gas-generating Drug Device for the Treatment of Pulmonary Hypertension2R42HL152921-02A1 | LESSING, GARY | INOVODEL, INC., DE | $1,467,953 | ZRG1 |
| 2023 | A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome2R42AI132047-03 | BOTTEN, JASON W.MURAD, JOANA M | CELDARA MEDICAL, LLC, NH | $1,000,000 | ZRG1 |
| 2023 | Lipid Receptor GPR31 as a Target for Anti-Thrombotic and Stroke Therapy2R42HL160429-02 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $999,799 | ZRG1 |
| 2023 | SensiTrak: Automated Assessment of Forelimb Sensation2R44NS120748-02 | SANCHEZ, CAMILO ANDRES | VULINTUS, LLC, TX | $982,150 | ZRG1 |
| 2023 | Controlled-release Microbeads to Replace Growth Factors in Fetal Bovine Serum2R42GM142345-02 | ROBERTS, KRISTINASTERN, JEFFREY H | STEMCULTURES, LLC, NY | $903,045 | ZRG1 |
| 2023 | Targeted ColQ gene therapy for Congenital Myasthenic Syndromes1R42NS127713-01A1 | MASELLI, RICARDO ANIBALSEPULVEDA, PATRICIO | AMPLO BIOTECHNOLOGY, INC., MD | $493,111 | ZRG1 |
| 2023 | Inducible HMGB1 antagonist for viral-induced acute lung injury.1R41HL167254-01 | BLANCO, JORGE CVOGEL, STEFANIE N. | SIGMOVIR BIOSYSTEMS, INC., MD | $488,080 | ZRG1 |
| 2023 | Development of Novel Small Molecule Anti-Fibrotic Agent for the Treatment of Systemic Scleroderma1R41HL167548-01 | ALEGRIA, ESTHER M | APIE THERAPEUTICS, INC., NC | $452,422 | ZRG1 |
| 2023 | Aerosolized Chemically Modified Tetracycline Nanoformulation for the Treatment of Acute Respiratory Distress Syndrome1R42HL166050-01A1 | KOLLISCH-SINGULE, MICHAELA CHRISTINALUO, JUNTAO | CMTX BIOTECH, INC., NY | $426,744 | ZRG1 |
| 2023 | Controlled Gradient Release of Biologics: Enhanced Nerve Conduit for Long‐Gap Injury Repair1R41NS130907-01 | ROMERO-ORTEGA, MARIO IGNACIO | PIONEER NEUROTECH INC., MA | $422,015 | ZRG1 |
| 2023 | A decellularized porcine placenta matrix hydrogel for management of radiation-induced proctitis1R41CA272043-01A1 | LI, JIAN JIAN | BRIOPRYME BIOLOGICS, INC., CA | $400,000 | ZRG1 |
| 2023 | Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy1R41EY034773-01 | ANDLEY, USHA PHAMRAH, PEDRAM | AFFIRMED PHARMA, LLC, TX | $341,302 | ZRG1 |
| 2023 | A novel producer cell line for more efficient manufacturing of viral vector systems1R41TR004231-01A1 | HAMM, ELAINE | CLAIRIGENE, LLC, NC | $330,532 | ZRG1 |
| 2023 | Leptin Receptor Agonist to Treat Sleep Disordered Breathing1R41HL167326-01 | KRAUS, CARL NEILPOLOTSKY, VSEVOLOD Y | ARREVUS, INC., NC | $319,944 | ZRG1 |
| 2023 | Using in-vivo Real-time Biosensor to Evaluate Prodrugs Designed to Prolong Therapeutic Effects for Smoking Cessation.1R41DA056334-01A1 | BETLEY, JOHN NICHOLASLEE, PETER H | SPACERX LLC, VA | $318,605 | ZRG1 |
| 2023 | Development of a treatment for durable remission of HIV using transposon engineered CAR-T and NK cells1R41AI170186-01A1 | ATHANASIOU, MARIA CONSTANCESKINNER, PAMELA J | MARPAM PHARMA, LLC, MN | $306,500 | ZRG1 |
| 2023 | Genetic adjuvants to elicit neutralizing antibodies against HIV1R43MH133246-01 | HARTIGAN-O'CONNOR, DENNIS J.SPARGER, ELLEN ELIZABETH | TENDEL THERAPIES INC., CA | $300,930 | ZRG1 |
| 2023 | Next-generation nanomedicine for acute ischemic stroke1R41NS130812-01 | BRENNER, JACOB | NANOMUSE, LLC, NJ | $300,454 | ZRG1 |
| 2023 | Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development1R41HL167327-01 | HOFFMAN, STANLEY R | FIBROTHERAPEUTICS, INC., SC | $299,972 | ZRG1 |
| 2023 | Optimizing the synthesis of[18F]FTMP for commercial distribution1R41EB034141-01 | SELLMYER, MARK A | VELLUM BIOSCIENCES LLC, PA | $299,927 | ZRG1 |
| 2023 | Phosphatidylserine-blocking nanoparticles as improved anti-thrombotic with reduced bleeding risk1R41HL167303-01 | GRAY, BRIAN DAVID | MOLECULAR TARGETING TECHNOLOGIES, INC., PA | $299,890 | ZRG1 |
| 2023 | Development of a novel sensor for the real-time measurement of mitral coaptation force1R41HL167401-01 | GRINBERG, DANIELMEDIGO, ANTHONYRAPOPORT, BENJAMIN ISAAC | MITRALPRINT INC., MI | $299,577 | ZRG1 |
| 2023 | Structurally engineered furan fatty acids for the treatment of dyslipidemia and cardiovascular disease1R41HL167544-01A1 | SCHOPFER, FRANCISCO JOSE | FURANICA, INC., PA | $299,169 | ZRG1 |
| 2023 | A novel, non-antibiotic, microbiome-directed agent to prevent post-surgical infection1R42AI174369-01 | ALVERDY, JOHN C | COVIRA SURGICAL, IL | $299,066 | ZRG1 |
| 2023 | Amadorins as a Novel Oral Therapeutic for Diabetic Retinopathy1R41EY034725-01 | KHALIFAH, RAJA G | PRAETEGO, INC., NC | $298,940 | ZRG1 |
| 2023 | Evaluating the efficacy of Butyric acid pro-drug nanoparticle in retinal neuroprotection1R41EY034735-01 | BISWAL, MANAS R | NUTRIFORWARD, LLC, TX | $296,790 | ZRG1 |
| 2023 | Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs1R41ES034936-01 | ATTARIANI, HAMED | PROMETHEUS TECHNOLOGIES, LLC, OH | $275,554 | ZRG1 |
| 2023 | Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis1R41DK135167-01 | CASTELLINO, STEPHENNOWLING, TAMMY (TAMARA) | GLYCOPATH, INC, SC | $275,397 | ZRG1 |
| 2023 | Microfluidic technology platform as a continuous end-line process to inactivate pharmaceuticals1R41TR004324-01 | DIXON, ERIC PAUL | NIGHTHAWK BIOSCIENCES, INC., NC | $274,649 | ZRG1 |
| 2023 | Carbon Nanotube-Mediated Gene Transfer into Human T-cells for CAR-T HIV Therapy1R43MH133247-01 | BAKHT, OMARDICKERSON, IAN MSCHRLAU, MICHAEL GEORGE | ADVANCED GENE TRANSFER COMPANY, INC., NY | $273,754 | ZRG1 |
| 2023 | Feasibility of a mobile application for sleep and circadian rhythms in pediatric patients with acute lymphoblastic leukemia and their caregivers1R41HL164294-01A1 | WALCH, OLIVIA | ARCASCOPE, INC, VA | $273,613 | ZRG1 |
| 2023 | Development of an Effective Strategy to Block Nab Activity for AAV Brain Transduction1R41TR004338-01 | ASKEW, CHARLES H | NABGEN, INC., NC | $269,640 | ZRG1 |
| 2023 | TeleLine: Plug-n-Play Inline Respiratory Remote Data Acquisition System1R41NR021221-01 | CHOSET, HOWIEZUBIATE, BRETT | OMNIBUS MEDICAL DEVICES, LLC, PA | $259,611 | ZRG1 |
| 2023 | Glove-based Tactile Streaming of Braille Characters and Digital Images for the Visually Impaired1R41EY034738-01 | AUDETTE, MICHEL ALBERTEICHERMUELLER, MICHAELWALKER, BRUCE N | HAPTX INC., CA | $257,200 | ZRG1 |
| 2023 | Motion-Resistant Background Subtraction Angiography with Deep Learning: Real-Time, Edge Hardware Implementation and Product Development1R41HL164298-01A1 | ANSARI, SAMEER ACANTRELL, DONALD ROBINSONCHO, LEON | CLEARVOYA LLC, IL | $256,879 | ZRG1 |
| 2023 | Development of a portable beat-to-beat fetal ECG system1R41HD109072-01 | KRISHNAN, ANITASHEKHAR, RAJ | AUSCULTECH DX, LLC, MD | $256,322 | ZRG1 |
| 2023 | Development of recombinant VSV vaccines for emerging bunyaviruses1R41AI174426-01 | BATES, PAULCOCKA, LUIS | ADVAC THERAPEUTIC, LLC, PA | $255,454 | ZRG1 |
| 2023 | ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit1R41NR020458-01A1 | HETLAND, BREANNA D | SILICON CURES LLC, NE | $228,561 | ZRG1 |
| 2023 | Automating Assessment of Contextualization of Care During the Clinical Encounter1R41NR020667-01 | WEINER, SAUL J | INSTITUTE/PRACTICE/PROVIDER/PERF/ IMPROV, IL | $221,912 | ZRG1 |
| 2023 | Affordable, UV-, heat- and water-resistant radiochromic film composed of diacetylenes having chromophoric groups1R41GM146547-01A1 | PATEL, GORDHANBHAI NATHALALWATANABE, YOICHI | J P LABORATORIES, INC, NJ | $1 | ZRG1 |
| 2022 | Development of SP-A Derived Peptidomimetics for the Treatment of Asthma - Phase II2R42HL152942-02 | BOITANO, SCOTTKRAFT, MONICALEDFORD, JULIE GUNNELLSVAGNER, JOSEF | RAESEDO, LLC, AZ | $1,955,594 | ZRG1 |
| 2022 | Novel tetrahedron beam CT for point-of-care imaging in ear, nose and throat imaging2R42EB026401-02A1 | TOKER, EMREZHANG, TIEZHI | TETRAIMAGING, LLC, MO | $1,168,381 | ZRG1 |
| 2022 | Optimizing a Stapled-Peptide That Specifically Targets HSV-1 to Treat Herpes Ocular Keratitis2R42AI170552-02A1 | REITZ, ALLEN BERNARDRICCIARDI, ROBERT PAUL | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $1,050,000 | ZRG1 |
| 2022 | Portable Affordable Innovative and Smart Device-Coupled Electronic Fetal Monitoring System to Improve Rural Access to Obstetrics Services and Improve Outcomes in Rural Communities2R42MD015915-02 · under PA-20-265 | SHAH, SWATI | FETAL LIFE, LLC, KY | $1,022,015 | ZRG1 |
| 2022 | Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin2R42CA243954-02 · under PA-20-265 | SHAFIRSTEIN, GAL | POP BIOTECHNOLOGIES, INC, NY | $1,001,404 | ZRG1 |
| 2022 | Development of a novel accurate therapy for multiple sclerosis2R42AI141323-02A1 · under PA-20-265 | GALARZA-MUNOZ, GADDIEL | AUTOIMMUNITY BIOLOGIC SOLUTIONS, INC., TX | $1,000,000 | ZRG1 |
| 2022 | A method for accurate and sensitive detection of HIV drug-resistant minority variants2R42AI122855-02A1 · under PA-20-265 | WANG, GARY P. | MEDOSOME BIOTEC, LLC, FL | $999,999 | ZRG1 |
| 2022 | Enhanced MDx: a computational model to optimize pre-analytical pathogen isolation from whole blood2R42GM136084-02 | MILLER, CASS T | REDBUD LABS, INC., NC | $999,676 | ZRG1 |
| 2022 | Multivalent Adjuvant Immunization to Prevent Hospital Acquired Infections2R42AI145759-03 · under PA-20-265 | SPELLBERG, BRAD J | EXBAQ LLC, MD | $995,098 | ZRG1 |
| 2022 | A novel vaccine against mosquito-borne Zika virus based on mosquito salivary gland protein AgBR12R42AI142846-03 · under PA-20-265 | FIKRIG, EROL | L2 DIAGNOSTICS, LLC, CT | $988,360 | ZRG1 |
| 2022 | Mitofusin Agonists to Treat Neurodegenerative Disease2R42NS113642-03 · under PA-20-265 | DORN, GERALD W.HAUGER, DEBORAH ANN | MITOCHONDRIA IN MOTION, INC., MO | $968,715 | ZRG1 |
| 2022 | Robust Predictor of Colon Cancer Risk2R42CA232867-02A1 | OSTRER, HARRY | MORGAN AND MENDEL GENOMICS, INC., DE | $968,518 | ZRG1 |
| 2022 | Renal Therapeutic Angiogenesis Using the Novel Biologic ELP-VEGF2R42DK109737-02A1 | BIDWELL, GENE LEFLORE | LEFLORE TECHNOLOGIES, LLC, MS | $876,494 | ZRG1 |
| 2022 | Portable, affordable, quantitative microchip electrophoresis for hemoglobin A1C testing2R42DK119048-02 | GALEN, PETER | HEMEX HEALTH, INC., OR | $865,376 | ZRG1 |
| 2022 | MegaTrans – human transporter machine learning models2R42GM131433-02 | CHERRINGTON, NATHAN JEKINS, SEAN | COLLABORATIONS PHARMACEUTICALS, INC., NC | $864,767 | ZRG1 |
| 2022 | Teleconsent: Enabling informed consent for remote care and research2R42TR004277-02 · under PA-20-265 | WELCH, BRANDON M | DOXY.ME, LLC, SC | $863,404 | ZRG1 |
| 2022 | Novel methods to improve nuclease mediated homologous recombination2R42GM122181-02 · under PA-20-265 | ZHANG, JIFENG | ATGC, INC., MI | $854,843 | ZRG1 |
| 2022 | A universal droplet microfluidic platform for ultrahigh-throughput biocatalyst evolution2R42GM143989-02 | ABATE, ADAM R.PRINCE, ROBIN | FLUID DISCOVERY INC, CA | $837,842 | ZRG1 |
| 2022 | Development of the UValidate platform for the profiling of topically applied chemical agents.2R42ES032435-02 | ROSENTHAL, DEANSYKORA, PETER | AMELIA TECHNOLOGIES, LLC, DC | $809,224 | ZRG1 |
| 2022 | Development of Novel Melanocortin-4 Receptor Peptide Agonists for the Treatment ofMC4R Haploinsufficiency2R42DK127817-02 | SAWYER, TOMI K | COURAGE THERAPEUTICS, INC., MA | $806,879 | ZRG1 |
| 2022 | Protection of donor kidneys with synchronization modulation electric field (SMEF)2R42DK130764-02 | CHEN, WEILIU, RUISHENG | WR BIOTECH, LLC, FL | $803,313 | ZRG1 |
| 2022 | SciDAP: Scientific Data Analysis Platform2R42HG011219-02 | BARSKI, ARTEMKARTASHOV, ANDREY | DATIRIUM, LLC, OH | $802,500 | ZRG1 |
| 2022 | A Novel Remedy for Periodontal Bone Loss2R42DE028212-02 | LI, XINSAXENA, DEEPAK | PERIOMICS CARE, LLC, NY | $591,125 | ZRG1 |
| 2022 | A novel PEDF peptide mimetic for diabetic retinopathy2R42EY029192-02A1 | WEI, JI-YE | SKYRAN BIOLOGICS, INC., PA | $542,313 | ZRG1 |
| 2022 | Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome1R42NS129400-01 | DUNCKLEY, TRAVISHULME, CHRISTOPHER | ILUMINOS THERAPEUTICS, LLC, AZ | $498,634 | ZRG1 |
| 2022 | VasaPlex-based biologics for treatment of reperfusion injury after myocardial infarction1R41HL162161-01 · under PA-20-265 | SPEES, JEFFREY L | SAMBA BIOLOGICS INCORPORATED, VT | $498,271 | ZRG1 |
| 2022 | Broadly Accessible Technologies for Single-cell Joint Analysis of Transcriptome and Epigenome1R41MH128993-01 · under PA-20-265 | REN, BING | EPIGENOME TECHNOLOGIES, INC., CA | $450,000 | ZRG1 |
| 2022 | Wearable modular high-density diffuse optical tomography1R41MH131449-01 | TROBAUGH, JASON WAYNE | ESPERIMAGE LLC, MO | $432,674 | ZRG1 |
| 2022 | An Integrated Neurochemical/Electrophysiological Recording and Neuromodulation System for Basic and Clinical Research1R42NS125895-01A1 | BENNET, KEVIN ELLIOTTLEE, KENDALL | WINCS INTERNATIONAL, LLC, MN | $429,757 | ZRG1 |
| 2022 | Development of the GlycoHCCTyper for the early detection of HCC1R41CA268268-01 · under PA-20-265 | CASTELLINO, STEPHENMEHTA, ANAND S. | GLYCOPATH, INC, SC | $428,443 | ZRG1 |
| 2022 | Overcoming Breast Cancer Therapeutic Resistance by Multifunctional RNA Nanoparticles1R41CA277939-01 | ZHANG, XIAOTING | RNA NANOTHERAPEUTICS LLC, OH | $406,500 | ZRG1 |
| 2022 | Development of a novel antibody-drug conjugate for treating T-cell lymphoma.1R41CA275639-01 | LIN, FENG C | ABCON THERAPEUTICS, INC., OH | $402,680 | ZRG1 |
| 2022 | Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment1R41CA268623-01 · under PA-20-265 | NGWA, WILFREDSHILLING, ADAM | NANOCAN THERAPEUTICS CORPORATION, NJ | $400,000 | ZRG1 |
| 2022 | Molecular brush-conjugated antisense oligonucleotide as a pan-KRAS depletion agent1R42CA275425-01 | ZHANG, KE | PACDNA LLC, MA | $400,000 | ZRG1 |
| 2022 | Development of small molecule RPN13 inhibitors for Treatment of Glioblastoma1R41CA265463-01A1 | ANCHOORI, RAVI KUMAR | UP THERAPEUTICS, INC., MD | $400,000 | ZRG1 |
| 2022 | Targeting AML Mitochondria by Ceramide1R41CA275631-01 | OGRETMEN, BESIM | LIPO-IMMUNO TECH, LLC, SC | $400,000 | ZRG1 |
| 2022 | Targeting cadherin-11 in pancreatic cancer1R41CA275619-01 | DAKSHANAMURTHY, SIVANESAN | DIVINER THERAPEUTICS, LLC, VA | $400,000 | ZRG1 |
| 2022 | Next generation anti-cancer drugdelivering cement for bone metastasis patients1R42CA268629-01A1 | JANG, HAE LIN | CURER INC, MA | $399,999 | ZRG1 |
| 2022 | Chemosensitization of Glioblastoma by Propentofylline1R41CA268286-01A1 | TRAN, NHAN L | OLEOLIVE, INC., LA | $399,998 | ZRG1 |
| 2022 | App-Assisted Day Reconstruction to Reduce Treatment Burden and Logistic Toxicity in Cancer Patients1R41CA271962-01 | FAN, YINGLING | DAYNAMICA, INC., MN | $399,865 | ZRG1 |
| 2022 | Development of a novel personalized medicine platform using apheretically isolated circulating tumor cells to assess drug responsiveness in prostate cancer1R41CA268344-01 · under PA-20-265 | DRAKE, JUSTIN MICHAELPARTHASARATHY, JAYANT | ASTRIN BIOSCIENCES, INC., MN | $399,678 | ZRG1 |
| 2022 | Development of Natural Killer (NK) Cell Line-Derived Extracellular Vesicles as a New Treatment for Cancer1R41CA268300-01 · under PA-20-265 | KORNBLUTH, JACKI | VANQUISH BIO LLC, FL | $399,580 | ZRG1 |
| 2022 | Validating novel DNA repair deficient cancer therapy targets and small molecule compounds1R41CA275627-01 | LIPKIN, RICHARDLIPKIN, STEVEN M | ANANEO THERAPEUTICS INC., NY | $398,917 | ZRG1 |
| 2022 | Development of a small-molecule immunomodulator for the treatment of melanoma1R41CA261311-01A1 · under PA-20-265 | VAN DROSS, RUKIYAH | CLARADELE PHARMACEUTICALS, INC., NC | $398,242 | ZRG1 |
| 2022 | High-speed, portable reflectance confocal microscope (pRCM) for imaging skin cancer1R41CA261214-01A1 · under PA-20-265 | KANG, DONGKYUN | ARGOSMD, INC., CA | $398,209 | ZRG1 |
| 2022 | Development of Novel CD180-Based Cancer Immunotherapeutics1R41CA257531-01A1 · under PA-20-265 | CLARK, EDWARD AFULLER, DEBORAH H. | ABACUS BIOSCIENCE INC, WA | $398,040 | ZRG1 |
| 2022 | Development of novel, targeted small molecule inhibitors of DNA repair in high unmet need tumors-TNBC1R41CA272039-01 | CAMPBELL, JUDITH L | DNATWO, INC., CA | $397,221 | ZRG1 |
| 2022 | A Precision Medicine Tool for Optimal Personalized Treatment in Patients with Acute Myeloid Leukemia1R42CA272132-01A1 | MANTALARIS, ATHANASIOSPANOSKALTSIS, NICKI | SANICKA, INC, GA | $396,908 | ZRG1 |
| 2022 | Development of Therapeutic Cancer Vaccine1R41CA265459-01 · under PA-20-265 | SHEN, HAIFA | IMMUNOQ THERAPEUTICS INC., TX | $395,738 | ZRG1 |
| 2022 | Development of a tumor-retentive immunostimulant as adjunct therapy for solid tumor cancers1R41CA272024-01A1 | FORREST, MARCUS LAIRD | KINIMMUNE, INC., MO | $395,595 | ZRG1 |
| 2022 | Increasing Thiols for Improving T cell Immunotherapy1R41CA271958-01A1 | MEHROTRA, SHIKHAR | LIPO-IMMUNO TECH, LLC, SC | $394,167 | ZRG1 |
| 2022 | Development of novel pharmacotherapies for AUD1R41AA029365-01A1 · under PA-20-265 | ANDERSON, ETHAN MICHAELCOWAN, CHRISTOPHER W | NEUROEPIGENIX, LLC, SC | $392,942 | ZRG1 |
| 2022 | Development of liver homing PAR2 pepducins for the treatment of Hepatocellular Carcinoma1R41CA272065-01A1 | KULIOPULOS, ATHAN | OASIS PHARMACEUTICALS, MA | $392,485 | ZRG1 |
| 2022 | Development of (R,S')-MNF as a dual-targeted therapy for pancreatic cancer1R41CA275625-01 | HAN, HAIYONGWAINER, IRVING | PAZ PHARMACEUTICALS, DC | $385,139 | ZRG1 |
| 2022 | Novel Nasal Formulations Containing EC16 for Minimizing COVID-19-Associated Anosmia1R41DC020678-01 | HSU, STEPHEN | CAMELLIX, LLC, GA | $384,971 | ZRG1 |
| 2022 | Develop AAV9 gene replacement therapy for treating MPS I1R41NS127726-01A1 | FU, HAIYANMCCARTY, DOUGLAS M | NEUROGT, INC., NC | $378,882 | ZRG1 |
| 2022 | Profiling circulating metabolites for the diagnosis of pulmonary hypertension1R41HL158296-01A1 · under PA-20-265 | RAFIKOVA, OLGA | METFORA LLC, AZ | $373,684 | ZRG1 |
| 2022 | Development of a Novel, Targeted Small Molecule Inhibitor of the Nucleoside Salvage Pathway to Treat Optic Neuritis1R42EY034397-01 | SCHULTZ, KENNETH | TRETHERA CORPORATION, CA | $368,195 | ZRG1 |
| 2022 | Tolerability and Potency of Sequential and Repeated AAV Corneal Gene Therapy1R41EY034046-01 | HIRSCH, MATTHEW LOUIS | RAINBIO, INC., NC | $367,624 | ZRG1 |
| 2022 | Protease Stable N-Terminally Modified Therapeutic Peptides1R41DK131842-01A1 | KUMAR, KRISHNA | VELUM, INC., MA | $367,389 | ZRG1 |
| 2022 | Provenance attestation of human cells using physical unclonable functions1R41HG012884-01 | PERTSEMLIDIS, ALEXANDER | SYNTAXISBIO, INC., TX | $361,552 | ZRG1 |
| 2022 | Smart Toilet with Artificial Intelligence for Remote Management of Inflammatory Bowel Disease1R41DK131678-01A1 | GREGO, SONIA | COPRATA, INC., NC | $349,877 | ZRG1 |
| 2022 | Neural Stem Cell Extracellular Vesicle Treatment for Traumatic Brain Injury1R41NS122704-01A1 | STICE, STEVEN LWEST, FRANKLIN D | ARUNA BIOMEDICAL, INC., GA | $346,150 | ZRG1 |
| 2022 | An automated system to differentiate Kawasaki disease from febrile illness with real life clinical datasets in New York City1R41TR004351-01 | SCHILLING, JAMES W | HBI SOLUTIONS INC., CA | $345,852 | ZRG1 |
| 2022 | Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery1R41HL162397-01 · under PA-20-265 | MARSDEN, ALISON LWILSON, NATHAN MARSHALL | BIOGRAFT, INC., CA | $345,103 | ZRG1 |
| 2022 | Continuous Photoacoustic Monitoring of Neonatal Stroke in Intensive Care Unit1R41EB033758-01 | BOCTOR, EMAD MJIN, FENGKANG, JEEUNWANG, CHENCHIA | BRIMROSE TECHNOLOGY CORPORATION, MD | $344,468 | ZRG1 |
| 2022 | Ultrasensitive PSA Quantitation Using Smartphone to Reduce Prostate Cancer Monitoring Disparities1R41CA254653-01A1 | WANG, PING | INSTANOSIS, INC., DE | $341,668 | ZRG1 |
| 2022 | Improved Diagnosis of Shunt Malfunction with Automatic Quantification of Ventricular Space1R41NS125874-01 · under PA-20-265 | FENG, XUE | CARINA MEDICAL, LLC, VA | $339,999 | ZRG1 |
| 2022 | A digital tool for monitoring speech decline in ALS1R42DC019877-01A1 | GREEN, JORDAN RRAMANARAYANAN, VIKRAM | MODALITY.AI , INC, CA | $332,831 | ZRG1 |
| 2022 | Label-free, Multimodality Diffuse Reflectance and Polarization-Based Proximity Probe for Iatrogenic Nerve Injury Prevention During Surgical Procedures1R41EB032747-01A1 | BABA, JUSTIN | YAYA SCIENTIFIC, LLC, TN | $328,433 | ZRG1 |
| 2022 | Rusalatide Acetate (TP508) Mitigation of Genotoxic Radiation Damage in Human Lens Epithelial Cells1R41EY033583-01 · under PA-20-265 | ANDLEY, USHA PFRANK, STEVEN JAY | AFFIRMED PHARMA, LLC, TX | $327,510 | ZRG1 |
| 2022 | Development and Evaluation of an Integrated Biomarker Capture System for Use in Remote Trials1R41TR004224-01 | DAHNE, JENNIFER RENEE | MOUNTAINPASS TECHNOLOGY, LLC, MD | $324,084 | ZRG1 |
| 2022 | Implementation and validation of a lung x-ray interferometry imaging system, with applications to COPD, COVID-19 and other lung diseases1R41HL158414-01A1 · under PA-20-265 | MATTHEWS, KENNETH L | REFINED IMAGING, LLC, LA | $322,996 | ZRG1 |
| 2022 | Development of a Gectosome Therapy for Cardiovascular Diseases1R41HL162212-01 · under PA-20-265 | LIU, XUEDONG | VESICLE THERAPEUTICS INC., CO | $316,823 | ZRG1 |
| 2022 | Low cost, Broad Spectrum Cancer Vaccine Targeting Human Papillomavirus1R41CA271851-01 | PARDHE, MARY | VAXSYNA, INC., NH | $315,874 | ZRG1 |
| 2022 | An AI-based Multimodal Approach to Predict Pain in Postnatal Care Scenarios1R41HD109086-01A1 | MOUTON, PETER RANDOLPHSUN, YU | STEREOLOGY RESOURCE CENTER, INC., FL | $315,169 | ZRG1 |
| 2022 | Real-Time Quantitation of Transport Across Vascular-Tissue Interfaces in Organ-On-Chip Models Using In Situ Mass Spectrometry1R41GM145196-01 · under PA-20-265 | GERMAN, CARRIE | CFD RESEARCH CORPORATION, AL | $314,215 | ZRG1 |
| 2022 | Shim System for Removing ICD Artifacts from Patient Cardiac MR Images1R41HL166053-01 | CHEN, YUEHROVAT, MIRKO I.SCHMIDT, EHUD JERUHAM | MIRTECH, INC., MA | $309,942 | ZRG1 |
| 2022 | Screening for Alzheimer's Disease Based on Raman Spectroscopy of Blood1R41AG078073-01A1 | LEDNEV, IGOR K | EARLY ALZHEIMER'S DIAGNOSTICS LLC, NY | $306,974 | ZRG1 |
| 2022 | Rapid Drug Susceptibility Test for Tuberculosis1R41AI167101-01 · under PA-20-265 | CIRILLO, JEFFREY D. | PULMONESCENCE DIAGNOSTICS, INC., TX | $306,500 | ZRG1 |
| 2022 | Development of Host- Oriented Therapeutics Targeting Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),1R41AI172464-01 | HARTY, RONALD N | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $306,500 | ZRG1 |
| 2022 | Development of FosA Inhibitors to Potentiate Fosfomycin Activity in Gram-Negative Pathogens1R41AI172491-01 | WROBEL, JAY EDWARD | FOX CHASE CHEMICAL DIVERSITY CENTER, INC, PA | $306,500 | ZRG1 |
| 2022 | Design and Engineering of Biodegradable 3D Nanoprinted Microcarriers for HIV Drug Delivery1R41AI167166-01 · under PA-20-265 | FLANK, SHARONSOCHOL, RYAN DANIEL | INFRATRAC, INC., MD | $303,714 | ZRG1 |
| 2022 | Troponin Biosensor for Early Detection and Real-time Monitoring of Myocardial Infarction1R41HL164281-01 | ZENG, XIANGQUN | EZ LAB LIMITED LIABILITY COMPANY, MI | $301,253 | ZRG1 |
| 2022 | Development of a Peptide Therapy for Corneal Wound Healing1R41EY034062-01 | FLAVIN, MICHAEL | VISO THERAPEUTICS INC., IL | $300,889 | ZRG1 |
| 2022 | Development of a novel, non-hormonal female contraceptive device1R41HD111106-01 | MAN, EMILYWHITE, KATHARINE O'CONNELL | VENOVA TECHNOLOGIES, INC., MA | $300,067 | ZRG1 |
| 2022 | A capsule-based bioconjugate vaccine to prevent Klebsiella pneumoniae infections1R41AI167078-01 · under PA-20-265 | HARDING, CHRISTIAN | VAXNEWMO, LLC, MO | $300,000 | ZRG1 |
| 2022 | Novel Peptide Fusion Inhibitors for the Treatment of COVID-191R41AI162083-01A1 · under PA-20-265 | TARRAN, ROBERT | ELDEC PHARMACEUTICALS, INC., NC | $300,000 | ZRG1 |
| 2022 | Anti-inflammatory Activity of a Systemic STING Inhibitory Non-Nucleotide1R41AI167270-01A1 · under PA-20-265 | BARBER, GLEN N | STINGINN, LLC, FL | $300,000 | ZRG1 |
| 2022 | The re-activatable Yb-169 radiation source: a therapeutic medical device to reduce the risk of brachytherapy and increase adoption1R41CA268293-01 · under PA-20-265 | FLYNN, RYAN THOMAS | PXALPHA, LLC, IA | $300,000 | ZRG1 |
| 2022 | Treatment of Inflammatory Complications of Viral Pneumonia1R41AI162590-01A1 · under PA-20-265 | AGRAWAL, ANDY | RESPANA THERAPEUTICS, INC., PA | $300,000 | ZRG1 |
| 2022 | Developing Hepatoselective Hepatitis B Therapeutic Dihydroquinolizinone (DHQ) Molecules with Better Safety Profiles for Efficient HBsAg Reduction1R41AI167172-01 · under PA-20-265 | DU, YANMING | HARLINGENE LIFE SCIENCES LLC, PA | $300,000 | ZRG1 |
| 2022 | CCR5 immunotoxins as components of HIV cure regimens1R41AI165350-01A1 · under PA-20-265 | HARTIGAN-O'CONNOR, DENNIS J. | TENDEL THERAPIES INC., CA | $300,000 | ZRG1 |
| 2022 | Development of protease activity-based detector substrates for diagnosing Candida infections1R41AI170132-01 | LOHSE, MATTHEW B. | BIOSYNESIS, INC., CA | $300,000 | ZRG1 |
| 2022 | Anti-eosinophil Gene Therapy for Eosinophilic Esophagitis1R41AI165000-01A1 | CRYSTAL, RONALD G | ENYX THERAPEUTICS, LLC, NY | $300,000 | ZRG1 |
| 2022 | Development of Broad-Spectrum Cyclic Amphiphilic Peptides against Multidrug-Resistant Bacteria1R41AI164997-01A1 | KAZEMINY, ASSADTIWARI, RAKESH K | AJK BIOPHARMACEUTICAL LLC, CA | $300,000 | ZRG1 |
| 2022 | New Agents for the Treatment on Mycobacteria Avium Infections1R41AI165272-01A1 | WRIGHT, DENNIS L. | QUERCUS MOLECULAR DESIGN, LLC, CT | $300,000 | ZRG1 |
| 2022 | Development of a Pre-Exposure Vaccine for Population-Level ProtectionAgainst Staphylococcus aureus Infection1R41AI167137-01A1 | BUBECK WARDENBURG, JULIANE | FORWARD DEFENSE, LLC, MO | $300,000 | ZRG1 |
| 2022 | Computer-based Learning to Enhance ADRD Care in Prison: Just Care for Dementia1R41AG078103-01 | LOEB, SUSAN JAYNE | KLEIN BUENDEL, INC., CO | $300,000 | ZRG1 |
| 2022 | Nanoimmunotherapy for chronic immune-mediated diseases1R41AI170413-01 | HORWITZ, DAVID A | GENERAL NANOTHERAPEUTICS, LLC, CA | $300,000 | ZRG1 |
| 2022 | Development and characterization of HIV-1 Tat degraders1R41AI170323-01 | VALENTE, SUSANA T | THIMBLE THERAPEUTICS, INC., CA | $300,000 | ZRG1 |
| 2022 | Developing generalized engineering tools to create enhanced phage therapy for the clinic and commercialization1R41AI165185-01A1 | MCBRIDE, ROBERT | FELIX BIOTECHNOLOGY, INC., CA | $300,000 | ZRG1 |
| 2022 | Rapid Viral Diagnostic Test by Digital Plasmonic Nanobubbles1R41AI170408-01A1 | QIN, ZHENPENG | AVSANA LABS INCORPORATED, TX | $300,000 | ZRG1 |
| 2022 | A novel CAR-T cell therapy for the one-time treatment of chronic HIV infection in patients who are not ART suppressed1R42AI167175-01A1 | ATHANASIOU, MARIA CONSTANCESKINNER, PAMELA J | MARPAM PHARMA, LLC, MN | $300,000 | ZRG1 |
| 2022 | Development and optimization of a nitric oxide releasing microparticle-basedtopical treatment for onychomycosis1R41AI165204-01A1 | DRAGANSKI, ANDREW RNOSANCHUK, JOSHUA D | ZYLO THERAPEUTICS, INC., SC | $300,000 | ZRG1 |
| 2022 | A Normal Paradigm to Monitor Perinatal Asphyxia Using A Combined Ultrasound-Neuromodulation and Photoacoustic-Imaging Device1R41EB033751-01 | BOCTOR, EMAD MHARRAZ, MAGEDTRIVEDI, SUDHIR BWANG, CHENCHIA | BRIMROSE TECHNOLOGY CORPORATION, MD | $300,000 | ZRG1 |
| 2022 | Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings1R41AI162258-01A1 · under PA-20-265 | STEVENSON, MARIO | DISCIDIUM BIOSCIENCES, LLC, FL | $299,999 | ZRG1 |
| 2022 | Using novel pre-harvest, resistance-conferring treatments to prevent foodborne pathogenic outbreaks in produce1R41AI170268-01A1 | MANOHAR, MURLI | ASCRIBE BIOSCIENCE INC., NY | $299,999 | ZRG1 |
| 2022 | AIDen: An AI-empowered detection and diagnosis system for jaw lesions using CBCT1R41DE031485-01 · under PA-20-265 | LI, JINGLURE, FLEMING Y. M.SETZER, FRANK CARSTEN MARTIN | MS TECHNOLOGIES CORPORATION, MD | $299,987 | ZRG1 |
| 2022 | The Butterfly BVM, a Novel Resuscitator to Prevent Hyperventilation in Pediatric Resuscitation1R41HD110310-01A1 | MERRELL, JONATHAN | COMPACT MEDICAL INC., IN | $299,973 | ZRG1 |
| 2022 | An additive solution to expand the lung transplant organ pool1R41HL164161-01 | CHATTERJEE, SHAMPAFISHER, ARON B. | PEROXITECH, LLC, PA | $299,931 | ZRG1 |
| 2022 | Novel Therapeutics for Interstitial Lung Disease: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development1R41HL164283-01A1 | HOFFMAN, STANLEY R | FIBROTHERAPEUTICS, INC., SC | $299,930 | ZRG1 |
| 2022 | Non-catalytic FAK inhibitors as novel therapeutics for lung fibrosis1R41HL162392-01 · under PA-20-265 | KNOX, KENNETH SMARLOWE, TIMOTHY A | FAKNOSTICS, LLC, AZ | $299,905 | ZRG1 |
| 2022 | Low Dose Oral Carbon Monoxide Therapeutic for Virus-Induced Lung Injury1R41AI164948-01A1 | GOMPERTS, EDWARDOTTERBEIN, LEO E | HILLHURST BIOPHARMACEUTICALS, INC., CA | $299,894 | ZRG1 |
| 2022 | A rapid test for congenital syphilis screening1R41HD107895-01 · under PA-20-265 | FRALEY, STEPHANIE IRENESINHA, MRIDU | MELIOLABS INC., CA | $299,891 | ZRG1 |
| 2022 | Repurposing CRH antagonists for the treatment of endometriosis1R41HD109055-01A1 | APPLEYARD, CAROLINE BTORRES-REVERON, ANNELYN | SUR180 THERAPEUTICS, LLC, TX | $299,864 | ZRG1 |
| 2022 | Human T cell Lymphotropic Virus Vaccine development1R41AI165061-01A1 | BARBER, GLEN N | STINGINN, LLC, FL | $299,860 | ZRG1 |
| 2022 | F plus G RSV VLP Vaccine for Improved Safety and Efficacy1R41AI167226-01 · under PA-20-265 | ANDERSON, LARRY J | RAZI PHARMA LLC, GA | $299,791 | ZRG1 |
| 2022 | A multivalent O-antigen bioconjugate vaccine for the prevention of Klebsiella pneumoniae infections1R42AI165116-01A1 | HARDING, CHRISTIAN | VAXNEWMO, LLC, MO | $299,238 | ZRG1 |
| 2022 | A Genetically Encoded Phosphorescent, Electron Dense Probe for Correlative Light and Electron Microscopy1R41GM148117-01 | LAWRENCE, CHARLES MARTINLEWIS, KEVIN MICHAEL | PHOTON BIOSCIENCES, LLC, WA | $299,225 | ZRG1 |
| 2022 | Biomarker-enhanced Artificial Intelligence-Based Pediatric Sepsis Screening Tool Towards Early Recognition and Personalized Therapeutics1R41AI167224-01A1 | KOUTROULIS, IOANNISVELEZ, CARMELO ELLIOT | COMPUTER TECHNOLOGY ASSOCIATES, INC., CA | $299,093 | ZRG1 |
| 2022 | A web-based platform to support team-based genome diagnostics1R41HG012536-01 | WARD, ALISTAIR | FRAMESHIFT LABS, INC., MA | $298,855 | ZRG1 |
| 2022 | Developing Vertebrate-Specific Replication-Defective Dengue Virus as Novel Single-CycleDengue Vaccine Candidate1R41AI162366-01A1 · under PA-20-265 | PANG, XIAOWU | TENGEN BIOMEDICAL CO., MD | $298,530 | ZRG1 |
| 2022 | Targeted delivery of novel miRNA-based therapeutics for pneumonia-induced acute lung injury1R41AI155327-01A1 · under PA-20-265 | AKERLEY, BRIAN | ADVAC THERAPEUTIC, LLC, PA | $296,926 | ZRG1 |
| 2022 | Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy1R41AI165102-01A1 | AMARASINGHE, GAYA K.LIU, GAI | MICROBIOTIX, INC, MA | $296,536 | ZRG1 |
| 2022 | A Novel Bacterially-derived Product to Enhance Immunity and Response to Immune Checkpoint Therapy1R41AI170290-01 | KOH, ANDREW | AUMENTA BIOSCIENCES, INC., TX | $289,194 | ZRG1 |
| 2022 | Accessible and Robust High-Throughput Western Blotting for Small Sample Sizes1R41GM148112-01 | BIRTWISTLE, MARC R. | BLOTTING INNOVATIONS, LLC, SC | $288,767 | ZRG1 |
| 2022 | Using Cardiac Targeting Peptide to deliver miRNA for molecular reversal of heart failure1R41HL164212-01 | GALLICANO, G IAN | VIVASC THERAPEUTICS INC., PA | $284,668 | ZRG1 |
| 2022 | A Deep Learning Model to Quantify Arteriosclerosis in Donor Kidney Biopsies1R41DK135161-01 | GAUT, JOSEPH PSWAMIDASS, VICTORIA G | NEWVENTUREIQ, LLC, MO | $279,951 | ZRG1 |
| 2022 | Hale: A Mobile-Connected Medical Vaporizer that Alleviates Nicotine Dependence1R41DA057798-01 | ISRAEL, JOSHUA | HAVA HEALTH INC, PA | $278,283 | ZRG1 |
| 2022 | Solving Sepsis: Early Identification and Prompt Management Using Machine Learning1R42GM144999-01 · under PA-20-265 | PATEL, MANESH R | COHERE-MED, INC., CA | $275,766 | ZRG1 |
| 2022 | Optimizing Composition and Delivery of a Novel RNA Therapy for Glioblastoma1R41CA278074-01 | MOCH, KENNETH | TERNALYS THERAPEUTICS, INC., NC | $275,766 | ZRG1 |
| 2022 | Development of a molecular-level skin condition diagnostic for precision medicine1R41AR082172-01 | SHERROD, STACY D. | FINALLY, LLC, TN | $275,764 | ZRG1 |
| 2022 | Next-Generation Expressive Personalized Voices for Speech-Generating Devices1R41DC020693-01 | BUNNELL, H TIMOTHYHERTZ, SUSAN R | SYNFONICA, LLC, NY | $275,752 | ZRG1 |
| 2022 | Development and Pre-Clinical Testing of Antimicrobial PEKK/Silicon Nitride Trauma Plates with Carbon Fiber Reinforcement1R41AR082266-01 | BOCK, RYAN | SINTX TECHNOLOGIES, INC., UT | $275,747 | ZRG1 |
| 2022 | An AI assistance tool to guide novice practitioners in the competent performance of flexible video laryngoscopy1R41EB034186-01 | BHATTI, NASIR ISLAMWITTE, DAN | PERCEPTRON HEALTH, INC., NY | $275,713 | ZRG1 |
| 2022 | Development of an improved intranasal vaccine against influenza1R41AI167146-01A1 | AMANNA, IAN JAMESSLIFKA, MARK K | NAJIT TECHNOLOGIES, INC., OR | $275,107 | ZRG1 |
| 2022 | Evaluation of a beta cell replacement therapy combined product that avoids the need for immunosuppression via localized induction of immune tolerance1R41DK135191-01 | COHEN, DENA E | REGENERATIVE MEDICAL SOLUTIONS, INC., IL | $274,984 | ZRG1 |
| 2022 | Glycoengineering of CHO cells to express recombinant alpha-1 antitrypsin1R41HL164260-01 | LEWIS, NATHAN ENOCH | NEUIMMUNE BIOLOGICS, INC., MD | $274,441 | ZRG1 |
| 2022 | EPICERTIN for Mucosal Healing in Ulcerative Colitis1R41DK131634-01A1 | TUSE, DANIEL | GROW BIOMEDICINE LLC, CA | $273,556 | ZRG1 |
| 2022 | Targeting the eNAMPT/TLR4 pathway to reduce Inflammatory Bowel Disease severity1R42DK135208-01 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $269,233 | ZRG1 |
| 2022 | Feasibility study of novel hand hygiene formulations against bacterial spore infection1R41AI172420-01 | HSU, STEPHEN | CAMELLIX, LLC, GA | $266,592 | ZRG1 |
| 2022 | Optimization of a nanoparticle-based topical PDE5i formulation for treatment of erectile dysfunction1R41DK129147-01A1 | DRAGANSKI, ANDREW R | ZYLO THERAPEUTICS, INC., SC | $263,446 | ZRG1 |
| 2022 | Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapies1R41EY033603-01 · under PA-20-265 | HIRSCH, MATTHEW LOUIS | EPIGENOS BIOSCIENCE, INC., NC | $263,372 | ZRG1 |
| 2022 | Cell permeant peptidomimetics to prevent delayed vasospasm and neurological deficits after subarachnoid hemorrhage1R41NS122656-01A1 · under PA-20-265 | BROPHY, COLLEEN M | VASAMETRIX LLC, TN | $261,863 | ZRG1 |
| 2022 | Clinical Decision Support System to Optimize Neonatal Nutrition and Growth1R41HD109038-01 | KING, WILLIAM E | MEDICAL PREDICTIVE SCIENCE CORPORATION, VA | $261,158 | ZRG1 |
| 2022 | Rational design of AAV vectors with human hepatocyte tropism and neutralizing antibody evasion1R41DK133021-01A1 | LI, CHENGWEN | BEDROCK THERAPEUTICS, INC., NC | $261,080 | ZRG1 |
| 2022 | ACSS2 inhibition in treating Alcohol Abuse1R41AA030516-01 | BECKER, HOWARD C.CHABOUB, LESLEY S. | EPIVARIO, LLC, PA | $259,971 | ZRG1 |
| 2022 | Microwave-Enhanced Microreactor for Ultrafast Detection of Protein Biomarkers1R41GM146522-01 | RAY, STEVENSU, XIAOLI | VIC FOUNDRY, INC., AR | $259,878 | ZRG1 |
| 2022 | Targeting the P Selectin Pathway to Improve ARDS Survival1R41HL164154-01 | MIELE, STANLEY | AQUALUNG THERAPEUTICS CORP., FL | $259,613 | ZRG1 |
| 2022 | Preclinical Development of a Novel eNAMPT-Neutralizing mAb for Pulmonary Hypertension1R42HL164300-01 | GARCIA, JOE G. N. | AQUALUNG THERAPEUTICS CORP., FL | $259,613 | ZRG1 |
| 2022 | Feasibility testing of a novel AI-enabled, cloud-based ECG diagnostic solution to enable fast and affordable diagnosis in long-term continuous ambulatory ECG monitoring1R41HL160317-01A1 | FANG, BINPARIKH, PUJASCHOENFELD, ELINOR R.ZHANG, PENGZHAO, BIN | ZBEATS, INC., NY | $259,613 | ZRG1 |
| 2022 | Highly-sensitive, rapid and low cost plasmonic assay platform for Lyme disease diagnosis1R41AI167161-01A1 | CADY, NATHANIEL CHARLESGUIGNON, ERNEST FITCHSTRLE, KLEMEN | CIENCIA, INC., CT | $259,613 | ZRG1 |
| 2022 | CuffLink: Remotely Monitored Rotator Cuff Repair Rehabilitation at Home1R41AR079357-01A1 | BELL, KEVIN MLAMBIASE, JENNIFERMCCLINCY, MICHAEL | ELIZUR CORPORATION, PA | $259,612 | ZRG1 |
| 2022 | Microfluidic Technology for Concurrent Assessment of Red Blood Cell Adhesion and Deformability1R42HL162214-01 · under PA-20-265 | FEDERICI, CHIARAGURKAN, UMUT A. | BIOCHIP LABS, INC., OH | $259,611 | ZRG1 |
| 2022 | Development of Modified Caveolin-1 Scaffolding Domain Peptides with Improved Pharmacological Properties as Therapeutic Agents for Scleroderma Skin Disease1R41AR081740-01 | HOFFMAN, STANLEY R | FIBROTHERAPEUTICS, INC., SC | $259,601 | ZRG1 |
| 2022 | Leveraging platelet signal transduction for personalized antiplatelet therapy1R41HL150951-01A1 | BARRIOS, DAVID | PLATELETDIAGNOSTICS, LLC, MA | $259,586 | ZRG1 |
| 2022 | Multispectral Sensor for Chemical Composition Analysis of Ultrafine Aerosols in Air Quality Assessment1R42ES034684-01 | MAMISHEV, ALEXANDER V | SPECTREE INC., WA | $259,573 | ZRG1 |
| 2022 | Point-of-care microdevices for simultaneous detection of multiple pertussis-like respiratory diseases from Bordetella species1R41AI162477-01A1 · under PA-20-265 | LI, XIUJUN | MICROBIOCHIP DIAGNOSTICS LLC, TX | $259,565 | ZRG1 |
Showing the 200 most recent of 1,738 awards.
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.